1012058-78-4

Basic information

• Product Name: Sorafenib related compound 10
• Synonyms: Sorafenib related compound 10;Sorafenib Related Compound A;Sorafenib Impurity 11
• CAS NO: 1012058-78-4
• Molecular Formula: C₂₀H₁₃ClF₃N₃O₄
• Molecular Weight: 451.7831296
• Mol File: 1012058-78-4.mol

Chemical Properties

• Boiling Point: 510.3±50.0 °C(Predicted)
• Appearance: /
• Density: 1.549±0.06 g/cm3(Predicted)
• PKA: 1.01±0.50(Predicted)
• CAS DataBase Reference: Sorafenib related compound 10(CAS DataBase Reference)
• NIST Chemistry Reference: Sorafenib related compound 10(1012058-78-4)
• EPA Substance Registry System: Sorafenib related compound 10(1012058-78-4)

Safety Data

• Hazardous Substances Data: 1012058-78-4(Hazardous Substances Data)

Usage

Uses

Used in Oncology:
Sorafenib related compound 10 is used as an antineoplastic agent for its potential role in cancer treatment. It targets multiple kinases that promote angiogenesis, making it a promising candidate for the development of targeted therapies against various types of cancer.
Used in Drug Development:
Sorafenib related compound 10 is used in drug development as a lead compound for the synthesis of novel kinase inhibitors. Its structure and activity can be further optimized to improve its potency, selectivity, and pharmacokinetic properties, leading to the discovery of more effective and safer anticancer drugs.
Used in Research:
Sorafenib related compound 10 is used in research as a tool compound to study the role of RAF kinase and receptor tyrosine kinases in cancer progression and angiogenesis. It can help researchers understand the molecular mechanisms underlying these processes and identify potential therapeutic targets for cancer treatment.

Upstream product

• 64064-56-8 ethyl 4-chloropyridine-2-carboxylate 
• 573673-43-5 methyl 4‐(4‐(3‐(4‐chloro‐3‐(trifluoromethyl)phenyl)ureido)phenoxy)picolinate 
• 123-30-8 4-amino-phenol 
• 284461-73-0 sorafenib 
• 871555-75-8 (4-chloro-3-trifluoromethylphenyl)carbamic acid phenyl ester 
• 98-98-6 2-Picolinic acid 
• 53750-66-6 4-chloro-pyridine-2-carbonyl chloride 
• 1097726-88-9 tert-butyl 4-(4-aminophenoxy)picolinate 
• 220000-86-2 tert-butyl 4-chloropyridine-2-carboxylate 
• 5470-22-4 4-chloropicolinic acid 
• 327-78-6 4-chloro-3-(trifluoromethyl)phenyl isocyanate 
• 320-51-4 4-chloro-3-trifluoromethyl-aniline 
• 1097726-89-0 tert-butyl 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)picolinate 

Downstream Products

• 1012058-79-5 (R)-methyl 2-(4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)picolinamido)propanoate 
• 1097726-90-3 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methoxypicolinamide 
• 573673-43-5 methyl 4‐(4‐(3‐(4‐chloro‐3‐(trifluoromethyl)phenyl)ureido)phenoxy)picolinate 
• 1130115-44-4 N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-(methyl-d₃)aminoformyl)-4-pyridyloxy)phenyl)urea 
• 1333386-17-6 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxyl)-2-(N-1’,1’,1’-trideuteromethyl)pyridine amide p-toluenesulfonate 
• 284461-73-0 sorafenib 

Relevant articles and documents

Preparation method and application of sorafenib photoaffinity probe molecule based on halogen intermediate

The invention discloses a preparation method and application of a sorafenib photoaffinity probe molecule based on a halogen intermediate, and relates to the technical field of biological medicines. The preparation method of the sorafenib photoaffinity pro

Preparation method and application of probe molecule containing photoaffinity group diazirine

The invention discloses a preparation method and application of a probe molecule containing a photoaffinity group diazirine, relates to the technical field of biological medicines, and solves the problems that a large fluorescent molecule needs to be connected to a drug molecule and the photocrosslinking activity of the probe molecule is weak in the existing target confirmation technology. 2-(3-(-3-butyne-1-yl)-3H-bis(aziridin-3-yl) ethyl-1-amine is used as a linker, drug molecules react to obtain an intermediate product with monocarboxylic acid, and the linker and the intermediate product with monocarboxylic acid are condensed to obtain the photoaffinity probe molecule. According to the arrangement, the preparation method of the photoaffinity probe molecule is relatively simple, the linker contains the photoaffinity group diaziridine, the photocrosslinking activity of diaziridine is relatively high, and meanwhile, the feasibility of a photoaffinity labeling technology in the aspect of confirming a small molecule target is also verified.

PREPARATION AND USE OF MOLECULAR SITE TARGETED AND ACTIVATED KINASE INHIBITOR

Disclosed are molecularly targeted and activated kinase inhibitors and use thereof. Specifically, a compound represented by the following formula A or a pharmaceutically acceptable salt thereof, wherein X is a polar and a non-polar uncharged amino acid such as alanine, proline or threonine; A is alanine; N is asparagine; PABC is -NH-phenyl-CH2-O-; and Z is a drug molecule; wherein the lactobionic acid residue, XAN and PABC are linked to each other by an amide bond; PABC is bonded to Z by an ester group, i.e., -OC(O)-. ????????Lacto-XAN-PABC-Z?????(Formula A)

Photoaffinity probe molecule based on VEGFR-2 inhibitor (sorafenib) and preparation method thereof

The invention relates to a photoaffinity probe molecule based on a VEGFR-2 inhibitor (sorafenib) and a preparation method thereof. The amido bond of the sorafenib is hydrolyzed under the NaOH (sodiumhydroxide) alkaline condition, so as to obtain an interm

RAF-DEGRADING CONJUGATE COMPOUNDS

The present disclosure provides, inter alia, RAF-Degrading Conjugate Compounds that are useful in the treatment of cancer and other RAF related diseases. Also provided are, pharmaceutical compositions, methods of treatment, and kits comprising a RAF- Degrading Conjugate Compound.

METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA-DIPHENYLUREA

Methods and processes for preparation and production of deuterated ω-diphenylurea are disclosed. Especially, a kind of deuterated ω-diphenylurea compounds which can inhibit phosphokinase and the preparation method of N-(4-chloro-3-(trifluoromethyl)phenye-N′-(4-(2-(N-d3-methylcarbamoyl)-4-pridinyloxy)phenyl)urea are disclosed. The said deuterated diphenylurea compounds can be used for treating or preventing tumors and relative diseases.

Oximide derivatives and their therapeutical application

The present invention relates to a compound represented as the following Formula (I) and a pharmaceutical composition thereof wherein all substituents are as defined in the specification; and also relates to a method for treating or lessening the severity

RAF KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to Raf kinase inhibitors containing zinc-binding and their use in the treatment of Raf related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.